Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection

Clinical Immunology

Volumn 132, Issue 1, 2009, Pages 43-54

  Shi, Ming ^a   Fu, Junliang ^a   Shi, Feng ^a   Zhang, Bin ^a   Tang, Zirong ^a   Jin, Lei ^a   Fan, Zhenping ^a   Zhang, Zheng ^a   Chen, Liming ^a   Wang, Huifeng ^a   Lau, George K K ^b   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; Cytokine induced killer cell; Efficacy; Hepatitis B virus; Safety

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CYTOKINE; HEMOGLOBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL THERAPY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; KILLER CELL; LIVER FUNCTION; MALE; PRIORITY JOURNAL; SEROCONVERSION; TRANSFUSION; VIROLOGY; VIRUS INACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ADOPTIVE TRANSFER; ADULT; AGED; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FLOW CYTOMETRY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 67349100632     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.001     Document Type: Article

References (45)

1. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 3 (2005) 215-229
2. Maini M.K., and Bertoletti A. How can the cellular immune response control hepatitis B virus replication?. J. Viral. Hepatitis 7 5 (2000) 321-326
3. Kakimi K., Guidotti L.C., Yasuhiko K., and Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192 7 (2000) 921-930
4. Niederau K., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., and Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon-alpha for chronic hepatitis B. N. Eng. J. Med. 334 22 (1996) 1422-1427
5. Hoofnagle J.H., and di Bisceglie A.M. The treatment of chronic viral hepatitis. N. Eng. J. Med. 336 5 (1997) 347-356
6. Hussain M., and Lok A.S. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J. Viral. Hepatitis 6 3 (1999) 183-194
7. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., and Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 2 (2003) 292-297
8. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., and Gray D.F. One-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Eng. J. Med. 339 2 (1998) 61-68
9. Ilan Y., Nagler A., Adler R., Tur-kaspa R., Slavin S., and Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104 6 (1993) 1818-1821
10. Ilan Y., Nagler A., Shouval D., Ackerstein A., Or R., Kapelushnik J., Adler R., and Slavin S. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin. Exp. Immunol. 97 2 (1994) 299-302
11. Lau G.K., Lok A.S., Liang R.H., Lai C.L., Chiu E.K., Lau Y.L., and Lam S.K. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25 6 (1997) 1497-1501
12. Hui C.K., and Lau G.K. Advances in immunomodulating therapy of HBV infection. Int. J. Med. Sci. 2 1 (2005) 24-29
13. Lo C.M., Fung J.T., Lau G.K., Liu C.L., Cheung S.T., Lai C.L., Fan S.T., and Wong J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 37 1 (2003) 36-43
14. Shi M., Qian S., Chen W.W., Zhang H., Zhang B., Tang Z.R., Zhang Z., and Wang F.S. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin. Exp. Immunol. 147 2 (2007) 277-286
15. Akbar S.M., Horiike N., and Onji M. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J. Gastroenterol. 12 18 (2006) 2876-2883
16. Michel M.L., and Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J. Clin. Virol. 34 Suppl. 1 (2005) S108-S114
17. Yao X., Zheng B., Zhou J., Xu D.Z., Zhao K., Sun S.H., Yuan Z.H., and Wen Y.M. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25 10 (2007) 1771-1779
18. Vandepapeliere P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., Merican M.I., Win K.M., Trepo C., Cooksley G., Wettendorff M., and Ferrari C. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25 51 (2007) 8585-8597
19. Sun J., Gao Y., Chen H.S., Wang S.X., Li R.B., Jiang D., Wei L., and Wang Y. Transfusion of multi-factors activated immune cells as a novel treatment for patients with chronic hepatitis B. J. Clin. Virol. 35 1 (2006) 26-32
20. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., and Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174 1 (1991) 139-149
21. Verneris M.R., Karami M., Baker J., Javaswal A., and Negrin B.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103 8 (2004) 3065-3072
22. Wang F.S., Liu M.X., Zhang B., Shi M., Lei Z.Y., Sun W.B., Du Q.Y., and Chen J.M. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J. Gastroenterol. 8 3 (2002) 464-468
23. Shi M., Zhang B., Tang Z.R., Lei Z.Y., Wang H.F., Feng Y.Y., Fan Z.P., Xu D.P., and Wang F.S. Autologous cytokine-induced killer cell therapy in clinical trial phase is safe in patients with primary hepatocellular carcinoma. World J. Gastroenterol. 10 8 (2004) 1146-1151
24. Zhang J.Y., Zhang Z., Wang X., Fu J.L., Yao J., Jiao Y., Chen L., Zhang H., Wei J., Jin L., Shi M., Gao G.F., Wu H., and Wang F.S. PD-1 upregulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors, but not in long-term non-progressors. Blood 109 11 (2007) 4671-4678
25. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., Moss B., Sette A., and Chisari F.V. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181 3 (1995) 1047-1058
26. Webster G.J., Reignat S., Maini M.K., Whalley S.A., Ogg G.S., King A., Brown D., Amlot P.L., Williams R., Vergani D., Dusheiko G.M., and Bertoletti A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32 5 (2000) 1117-1124
27. Penna A., del Prete G.D., Cavalli A., Bertoletti A., D'Elios M.M., Sorrentino R., D'Amato M., Boni C., Pilli M., Fiaccadori F., and Ferrari C. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25 4 (1997) 1022-1027
28. Kaplan D.E., Sugimoto K., Newton K., Valiga M.E., Ikeda F., Aytaman A., Nunes F.A., Lucey M.R., Vance B.A., Vonderheide R.H., Reddy K.R., McKeating J.A., and Chang K.M. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132 2 (2007) 654-666
29. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78 11 (2004) 5707-5719
30. Sobao Y., Tomiyama H., Sugi K., Tokunaga M., Ueno T., Saito S., Fujiyama S., Morimoto M., Tanaka K., and Takiguchi M. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J. Hepatol. 36 1 (2002) 105-115
31. Bertoletti A., Constanzo A., Chisari F.V., Levrero M., Artini M., Sette A., Penna A., Giuberti T., Fiaccadori F., and Ferrari C. Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variants viruses carrying substitutions within the epitope. J. Exp. Med. 180 3 (1994) 933-943
32. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., McHutchison J.G., Alter H.J., and Chisari F.V. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 1 (2001) 267-276
33. Sprengers D., Stoop J.N., Binda R.S., Kusters J.G., Haagmans B.L., Carotenuto P., Artsen A., van der Molen R.G., and Janssen H.L. Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir. Ther. 12 7 (2007) 1087-1096
34. Chang K.M. Regulatory T cells in hepatitis C virus infection. Hepatol. Res. 37 Suppl. 3 (2007) S327-330
35. Fu J.L., Xu D.P., Liu Z.W., Shi M., Zhao P., Fu B.Y., Zhang Z., Yang H.Y., Zhang H., Zhou C.B., Yao J.X., Jin L., Wang H.F., Yang Y.P., Xing Y., and Wang F.S. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132 7 (2007) 2328-2339
36. Xu D.P., Fu J.L., Jin L., Zhang H., Zhou C.B., Zou Z.S., Zhao J.M., Zhang B., Shi M., Ding X.L., Tang Z.R., Fu Y.X., and Wang F.S. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177 1 (2006) 739-747
37. Lu P.H., and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo anti-tumor activity in mice with potent severe combined immunodeficiency. J. Immunol. 153 4 (1994) 1687-1696
38. Weng D.S., Zhou J., Zhou Q.M., Zhao M., Wang Q.J., Huang L.X., Li Y.Q., Chen S.P., Wu P.H., and Xia J.C. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother. 31 1 (2008) 63-71
39. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., and Koup R.A. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281 1-2 (2003) 65-78
40. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., and Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 7077 (2006) 669-670
41. Shin E.C., and Rehermann B. Taking the brake off T cells in chronic viral infection. Nat. Med. 12 3 (2006) 276-277
42. Chen L.E., Zhang Z., Chen W.W., Zhang Z.D., Li Y.G., Shi M., Zhang J.Y., Chen L.P., Wang S.D., and Wang F.S. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178 10 (2007) 6634-6641
43. Okazaki T., Iwai Y., and Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14 6 (2002) 779-782
44. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4 5 (2004) 336-347
45. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 23 (2005) 515-548